Cargando…

Treatment Intensification for Low-risk Metastatic Hormone-sensitive Prostate Cancer: The Time Is Now

Detalles Bibliográficos
Autor principal:	McKay, Rana R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2022
Materias:	Opinion: Open Science
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9525807/ https://www.ncbi.nlm.nih.gov/pubmed/36193417 http://dx.doi.org/10.1016/j.euros.2022.09.009

Ejemplares similares

Hormonal Intensification Should Start at the Low-risk Stage in Metastatic Prostate Cancer
por: Jazayeri, Seyed Behzad, et al.
Publicado: (2022)

Debate on Treating Oligometastatic Metastatic Hormone-sensitive Prostate Cancer: The Argument for New-generation Hormone Therapy and Radiation Therapy to the Prostate
por: Saad, Fred
Publicado: (2022)

Virtual Prostate Biopsy with Prostate-specific Membrane Antigen and Magnetic Resonance Imaging: Closer to Reality in a Subgroup of Prostate Cancer Patients?
por: Pomykala, Kelsey L., et al.
Publicado: (2022)

Abandon the Label of Clinically Insignificant Prostate Cancer
por: Mertens, Laura S., et al.
Publicado: (2022)

Diagnosis of Clinically Significant Prostate Cancer Diagnosis Without Histological Proof in the Prostate-specific Membrane Antigen Era: The Jury Is Still Out
por: Wenzel, Mike, et al.
Publicado: (2022)

Management of Late Relapses in Metastatic Testicular Germ Cell Tumors: Still a Challenge
por: Heidenreich, Axel
Publicado: (2021)

Prostate Cancer Diagnosis Without Histological Proof: Is Treating Images Reasonable?
por: Rouvière, Olivier, et al.
Publicado: (2022)

Sentinel Lymph Node Biopsy: A Great Opportunity for Personalized Radiotherapy in Prostate Cancer
por: Supiot, Stéphane, et al.
Publicado: (2023)

TREXIT Is Now: Should We Abandon the Transrectal Route for Prostate Biopsy? Yes
por: Grummet, Jeremy P., et al.
Publicado: (2021)

The Metaverse in Urology: Ready for Prime Time. The ESUT, ERUS, EULIS, and ESU Perspective
por: Checcucci, Enrico, et al.
Publicado: (2022)

Re-envisioning Patient Education and Public Awareness of Urological Cancers at the Time of the COVID-19 Pandemic
por: Pecoraro, Alessio, et al.
Publicado: (2022)

Management of Favorable-risk Advanced Renal Cell Carcinoma: Is Dual Therapy the Answer?
por: Kartolo, Adi, et al.
Publicado: (2021)

Visceral Metastasis Predicts Response to New Hormonal Agents in Metastatic Castration-Sensitive Prostate Cancer
por: Yekedüz, Emre, et al.
Publicado: (2023)

Early or Delayed Radical Cystectomy for High-risk Non–muscle-invasive Bladder Cancer: A Hard Dilemma to Solve
por: De Nunzio, Cosimo, et al.
Publicado: (2022)

Colorectal cancer screening: the time to act is now
por: Brenner, Hermann, et al.
Publicado: (2015)

Quantitative SPECT: the time is now
por: Dickson, John, et al.
Publicado: (2019)

Lower Urinary Tract Symptoms: A Unique Platform for Urologists’ Fundamental Role in Overall Health
por: Monaghan, Thomas F., et al.
Publicado: (2020)

Prehabilitation Programs Before Radical Prostatectomy: An Interesting Approach that Merits Further Evaluation
por: Isbarn, Hendrik
Publicado: (2020)

Orphaned Side-effects After Robot-assisted Radical Prostatectomy: Is the Retzius-sparing Approach Superior to the Standard Approach or Are the Data Just Not Mature Enough?
por: Würnschimmel, Christoph, et al.
Publicado: (2021)

A Precision Urodynamic Diagnosis is Essential for Successful Treatment of Lower Urinary Tract Dysfunction
por: Kuo, Hann-Chorng
Publicado: (2022)

Sex-specific Augmentation of Treatment Responses in Bladder Cancer
por: Chang, Kevin, et al.
Publicado: (2022)

Checklist for Transurethral Resection of Bladder Tumor (TURBT): A Step Forward in the Standardization for TURBT Reporting
por: Martínez-Piñeiro, Luis
Publicado: (2022)

Defining the Mycobiome in Bladder Cancer
por: Mercier, Benjamin D., et al.
Publicado: (2022)

Evolution and Implications of the Novel CAMUS Reporting and Classification System: From Rationale to End Product
por: Soliman, Christopher, et al.
Publicado: (2023)

The Decision to Surgically Resect Recurrent Renal Cell Carcinoma: More Evidence that Careful Case Selection by Surgeons Is Associated with Better Survival
por: Russo, Paul
Publicado: (2023)

COVID-19: Public and patient involvement, now more than ever
por: Murphy, Edel, et al.
Publicado: (2020)

Probiotic research in neonates with congenital gastrointestinal surgical conditions – Now is the time
por: Rao, Shripada C., et al.
Publicado: (2018)

Artificial intelligence—the future is now
por: Trolice, Mark P., et al.
Publicado: (2021)

Creating a Distinct Medication-Use System for Children at the Point of Care: The Time is Now
por: Parrish, Richard, et al.
Publicado: (2015)

Safety and Feasibility of Transperineal Targeted Microwave Ablation for Low- to Intermediate-risk Prostate Cancer
por: Oderda, Marco, et al.
Publicado: (2022)

Editorial Comment: Abiraterone in “High-” and “Low-risk” Metastatic Hormone-sensitive Prostate Cancer
por: Lott, Felipe
Publicado: (2020)

The decay of a B0 meson into a K*0 and an electron–positron pair in the LHCb detector, which is used for a sensitive test of lepton universality in the Standard Model
por: LHCb Experiment, LHCb Collaboration
Publicado: (2018)

High-risk Locally Advanced Prostate Cancer: Multimodal Treatment Is the Key
por: Terlizzi, Mario, et al.
Publicado: (2022)

Prostate-specific Membrane Antigen Positron Emission Tomography, Not Conventional Imaging, Should Be Performed for Primary Staging of High-risk Prostate Cancer
por: Ceci, Francesco, et al.
Publicado: (2021)

Magnetic Resonance Imaging–guided Active Surveillance of Prostate Cancer: Time to Say Goodbye to Protocol-based Biopsies
por: Giganti, Francesco, et al.
Publicado: (2022)

Miniature gastrointestinal endoscopy: Now and the future
por: McGoran, John J, et al.
Publicado: (2019)

ARASENS Trial: Should darolutamide now be added to androgen-deprivation therapy and docetaxel in patients with metastatic, hormone-sensitive prostate cancer?
por: Kumar, Naveen
Publicado: (2022)

GRAVITY PLAY: A co-creation session on changing risks and policy innovation, via juggling & acrobatics
por: Poulaillon, Jimmy
Publicado: (2023)

PARP inhibitors and metastatic castration-resistant prostate cancer: uture directions and pitfalls
por: Franza, A., et al.
Publicado: (2021)

TREXIT Is Now: Should We Abandon the Transrectal Route for Biopsy? A Three-continent Debate—No
por: Olivier, Jonathan, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_ed94o3crqpgpjimnd5h7r73ddu